CA2490142A1 - Formes dosifiees liquides titrables de medicaments labiles en milieu acide - Google Patents

Formes dosifiees liquides titrables de medicaments labiles en milieu acide Download PDF

Info

Publication number
CA2490142A1
CA2490142A1 CA002490142A CA2490142A CA2490142A1 CA 2490142 A1 CA2490142 A1 CA 2490142A1 CA 002490142 A CA002490142 A CA 002490142A CA 2490142 A CA2490142 A CA 2490142A CA 2490142 A1 CA2490142 A1 CA 2490142A1
Authority
CA
Canada
Prior art keywords
micro
granules
liquid
viscosity
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002490142A
Other languages
English (en)
Inventor
Rajneesh Taneja
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceuticals USA Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2490142A1 publication Critical patent/CA2490142A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des formulations pharmaceutiques comprenant des micro-granulés et un excipient liquide en suspension présentant un pH inférieur à 5,0 et une viscosité suffisante pour mettre lesdits micro-granulés en suspension. Lesdits micro-granulés contiennent généralement un IPP (inhibiteur de la pompe à protons) qui contribue de ce fait à la production de ladite formulation. L'invention concerne également des kits de production de ladite formulation servant à alléger les symptômes de troubles gastro-intestinaux ou de maladies associées.
CA002490142A 2002-07-03 2003-07-02 Formes dosifiees liquides titrables de medicaments labiles en milieu acide Abandoned CA2490142A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19023902A 2002-07-03 2002-07-03
US10/190,239 2002-07-03
PCT/US2003/020946 WO2004004690A1 (fr) 2002-07-03 2003-07-02 Formes dosifiees liquides titrables de medicaments labiles en milieu acide

Publications (1)

Publication Number Publication Date
CA2490142A1 true CA2490142A1 (fr) 2004-01-15

Family

ID=30114048

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002490142A Abandoned CA2490142A1 (fr) 2002-07-03 2003-07-02 Formes dosifiees liquides titrables de medicaments labiles en milieu acide

Country Status (5)

Country Link
EP (1) EP1572151A1 (fr)
JP (2) JP5148813B2 (fr)
CA (1) CA2490142A1 (fr)
MX (1) MXPA05000301A (fr)
WO (1) WO2004004690A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9901551B2 (en) * 2009-04-20 2018-02-27 Ambra Bioscience Llc Chemosensory receptor ligand-based therapies
SG189444A1 (en) 2010-10-19 2013-05-31 Elcelyx Therapeutics Inc Chemosensory receptor ligand-based therapies
CN103957894A (zh) * 2011-10-19 2014-07-30 R.P.谢勒技术有限公司 两相药物递送系统
GB2535130B (en) * 2014-09-29 2020-09-02 Veriton Pharma Ltd A Suspension
US10736855B2 (en) 2016-02-25 2020-08-11 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
GB202116644D0 (en) 2021-11-18 2022-01-05 Innovate Pharmaceuticals Ltd Liquid composition

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9301489D0 (sv) * 1993-04-30 1993-04-30 Ab Astra Veterinary composition
US5708017A (en) * 1995-04-04 1998-01-13 Merck & Co., Inc. Stable, ready-to-use pharmaceutical paste composition containing proton pump inhibitors
ATE500815T1 (de) * 1997-12-08 2011-03-15 Dietrich Rango Neue suppositoriumsform mit säureempfindlichem wirkstoff
DE19925710C2 (de) * 1999-06-07 2002-10-10 Byk Gulden Lomberg Chem Fab Neue Zubereitung und Darreichungsform enthaltend einen säurelabilen Protonenpumpenhemmer
WO2002045692A1 (fr) * 2000-12-07 2002-06-13 Altana Pharma Ag Preparation pharmaceutique sous forme de suspension contenant un ingredient actif labile en milieu acide
UA80393C2 (uk) * 2000-12-07 2007-09-25 Алтана Фарма Аг Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці

Also Published As

Publication number Publication date
WO2004004690A1 (fr) 2004-01-15
MXPA05000301A (es) 2005-03-31
JP2013028603A (ja) 2013-02-07
EP1572151A1 (fr) 2005-09-14
JP5148813B2 (ja) 2013-02-20
JP2005535661A (ja) 2005-11-24

Similar Documents

Publication Publication Date Title
US20080274200A1 (en) Dose titratable liquid dosage forms of acid labile drugs
JP6209237B2 (ja) 酸不安定性薬物の液体剤形
US20080292710A1 (en) Liquid Dosage Forms Of Acid Labile Drugs
ES2389844T3 (es) Forma de dosificación sólida que comprende inhibidor de la bomba de protones, y suspensión obtenida de ella
ES2399898T3 (es) Composiciones farmacéuticas de sabor enmascarado preparadas por coacervación
FI90393B (fi) Menetelmä oraalisen, farmaseuttisen valmisteen valmistamiseksi, joka on pysyvä värin muuttumista vastaan
US20120252848A1 (en) Liquid dosage forms of non-enterically coated acid-labile drugs
KR20040099265A (ko) 신규의 치환 벤즈이미다졸 제형 및 그 사용방법
KR20040047771A (ko) 신규의 치환 벤즈이미다졸 제형 및 그 사용방법
JP2011144168A (ja) 非腸溶性酸不安定性薬物の液体剤形
KR20020029668A (ko) 풍미 차단된 약제학적 액상 제제
JP2013028603A (ja) プロトンポンプ阻害剤の液体剤形
BR112021016421A2 (pt) Minimização de aglomeração, aeração e preservação do revestimento de composições farmacêuticas que compreendem ibuprofeno
US20150050336A1 (en) Taste Masking System For Non-Plasticizing Drugs
Johnson et al. Stability of esomeprazole capsule contents after in vitro suspension in common soft foods and beverages
JP2006522089A (ja) 被覆オキサゾリジノン粒子のための味のマスキング用ビヒクル
JPH0440327B2 (fr)

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead

Effective date: 20140429